Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study

Abstract Introduction Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of up...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Stamatios Gregoriou, Ioannis-Alexios Koumprentziotis, Ileana Afroditi Kleidona, Michail Bakakis, Eleni Hatzidimitriou, Theodora Douvali, Aikaterini Tsiogka, Styliani Mastraftsi, Aristeidis Vaiopoulos, Alexander Stratigos
Format:	Artigo
Język:	Inglês
Wydane:	Adis, Springer Healthcare 2025-01-01
Seria:	Dermatology and Therapy
Hasła przedmiotowe:	Atopic dermatitis Eczema JAK inhibitor Real-world Upadacitinib EASI
Dostęp online:	https://doi.org/10.1007/s13555-024-01334-6
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!